ArticleCureus2025
Pathologic Complete Response to Neoadjuvant Radiation Therapy in a Primary Pancreaticoduodenal High-Grade Sarcoma.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High-grade intra-abdominal sarcomas are a rare soft tissue malignancy with a high propensity to present in a locally advanced fashion. The role of radiation therapy (RT) in the management of intra-abdominal sarcomas is relatively under-reported, in contrast to its use in retroperitoneal or extremity sarcomas. We thereby present a case of a 63-year-old female presenting with abdominal pain, gastrointestinal (GI) bleeding, and weight loss, found to have a large, high-grade intra-abdominal pancreaticoduodenal sarcoma. Given ongoing bleeding, absence of actionable mutations, and surgical risk, she was treated with neoadjuvant RT (50 Gray in 25 fractions) using image-guided volumetric-modulated arc therapy. The patient tolerated treatment well with rapid and significant tumor regression, allowing for subsequent pancreaticoduodenectomy. Pathology revealed a complete pathologic response (ypT0N0M0) with no residual viable tumor. At 2.5 years post-treatment, she remains disease-free. This case highlights the potential role of neoadjuvant RT in achieving local control and facilitating curative resection in patients with high-grade intra-abdominal sarcomas. While evidence is limited, especially for visceral intra-abdominal sites, this report supports further investigation into RT as a component of multimodal therapy in select cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.